Bronnen:
Ray-Coquard L, et al. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (prs) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Abstract LBA2_PR. ESMO Congress 2019, 28 sept. Barcelona, Spanje. ,González Martín A, et al. Niraparib treatment in patients with newly diagnosed advanced ovarian cancer (OC). Abstract LBA1. ESMO Congress 2019, 28 sept. Barcelona, Spanje.,Coleman RL, et al. VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC). LBA3. ESMO Congress 2019, 28 sept. Barcelona, Spanje.
Ray-Coquard L, et al. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (prs) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Abstract LBA2_PR. ESMO Congress 2019, 28 sept. Barcelona, Spanje. ,González Martín A, et al. Niraparib treatment in patients with newly diagnosed advanced ovarian cancer (OC). Abstract LBA1. ESMO Congress 2019, 28 sept. Barcelona, Spanje.,Coleman RL, et al. VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC). LBA3. ESMO Congress 2019, 28 sept. Barcelona, Spanje.